Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review

被引:7
|
作者
Aldinc, Emre [1 ]
Campbell, Courtney [2 ]
Gustafsson, Finn [3 ]
Beveridge, Abigail [4 ]
Macey, Richard [4 ]
Marr, Laura [4 ]
Summers, Catherine [1 ]
Zhang, Dafang [5 ]
机构
[1] Alnylam Pharmaceut, Cambridge, MA 02115 USA
[2] Baylor Scott & White Heart & Vasc Hosp, Dallas, TX USA
[3] Univ Copenhagen, Rigshopsitalet, Copenhagen, Denmark
[4] Adelphi Values PROVETM, Bollington, England
[5] Brigham & Womens Hosp, Boston, MA USA
关键词
CARPAL-TUNNEL-SYNDROME; POLYNEUROPATHY TTR-FAP; CARDIAC AMYLOIDOSIS; LIGAMENTUM-FLAVUM; COMMON-CAUSE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; HEART-FAILURE; DEPOSITION; MUTATIONS;
D O I
10.1186/s12891-023-06853-5
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
BackgroundHereditary and wild-type transthyretin-mediated (ATTRv and ATTRwt) amyloidoses result from the misfolding of transthyretin and aggregation of amyloid plaques in multiple organ systems. Diagnosis of ATTR amyloidosis is often delayed due to its heterogenous and non-specific presentation. This review investigates the association of musculoskeletal (MSK) manifestations with ATTR amyloidosis and the delay from the onset of these manifestations to the diagnosis of ATTR amyloidosis.MethodsThis systematic review utilized Medline and EMBASE databases. Search criteria were outlined using a pre-specified patient, intervention, comparator, outcome, time, study (PICOTS) criteria and included: amyloidosis, ATTR, and MSK manifestations. Publication quality was assessed utilizing Joanna Briggs Institute (JBI) critical appraisal checklists.The search initially identified 7,139 publications, 164 of which were included. PICOTS criteria led to the inclusion of epidemiology, clinical burden and practice, pathophysiology, and temporality of MSK manifestations associated with ATTR amyloidosis. 163 publications reported on ATTR amyloidosis and MSK manifestations, and 13 publications reported on the delay in ATTR amyloidosis diagnosis following the onset of MSK manifestations.MethodsThis systematic review utilized Medline and EMBASE databases. Search criteria were outlined using a pre-specified patient, intervention, comparator, outcome, time, study (PICOTS) criteria and included: amyloidosis, ATTR, and MSK manifestations. Publication quality was assessed utilizing Joanna Briggs Institute (JBI) critical appraisal checklists.The search initially identified 7,139 publications, 164 of which were included. PICOTS criteria led to the inclusion of epidemiology, clinical burden and practice, pathophysiology, and temporality of MSK manifestations associated with ATTR amyloidosis. 163 publications reported on ATTR amyloidosis and MSK manifestations, and 13 publications reported on the delay in ATTR amyloidosis diagnosis following the onset of MSK manifestations.ResultsThe MSK manifestation most frequently associated with ATTR amyloidosis was carpal tunnel syndrome (CTS); spinal stenosis (SS) and osteoarthritis (OA), among others, were also identified. The exact prevalence of different MSK manifestations in patients with ATTR amyloidosis remains unclear, as a broad range of prevalence estimates were reported. Moreover, the reported prevalence of MSK manifestations showed no clear trend or distinction in association between ATTRv and ATTRwt amyloidosis.MSK manifestations precede the diagnosis of ATTR amyloidosis by years, and there was substantial variation in the reported delay to ATTR amyloidosis diagnosis. Reports do suggest a longer diagnostic delay in patients with ATTRv amyloidosis, with 2 to 12 years delay in ATTRv versus 1.3 to 1.9 years delay in ATTRwt amyloidosis.ResultsThe MSK manifestation most frequently associated with ATTR amyloidosis was carpal tunnel syndrome (CTS); spinal stenosis (SS) and osteoarthritis (OA), among others, were also identified. The exact prevalence of different MSK manifestations in patients with ATTR amyloidosis remains unclear, as a broad range of prevalence estimates were reported. Moreover, the reported prevalence of MSK manifestations showed no clear trend or distinction in association between ATTRv and ATTRwt amyloidosis.MSK manifestations precede the diagnosis of ATTR amyloidosis by years, and there was substantial variation in the reported delay to ATTR amyloidosis diagnosis. Reports do suggest a longer diagnostic delay in patients with ATTRv amyloidosis, with 2 to 12 years delay in ATTRv versus 1.3 to 1.9 years delay in ATTRwt amyloidosis.ConclusionThese findings suggest that orthopedic surgeons may play a role in the early diagnosis of and treatment referrals for ATTR amyloidosis. Detection of MSK manifestations may enable earlier diagnosis and administration of effective treatments before disease progression occurs.
引用
收藏
页数:37
相关论文
共 50 条
  • [1] Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review
    Emre Aldinc
    Courtney Campbell
    Finn Gustafsson
    Abigail Beveridge
    Richard Macey
    Laura Marr
    Catherine Summers
    Dafang Zhang
    BMC Musculoskeletal Disorders, 24
  • [2] History of polyneuropathy and musculoskeletal manifestations in patients with transthyretin-mediated amyloidosis with cardiomyopathy in APOLLO-B
    Grogan, Martha
    Bender, Shaun
    Kumar, Varun
    Capocelli, Kelley
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S69 - S69
  • [3] Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
    Nie, Tina
    Heo, Young-A
    Shirley, Matt
    DRUGS, 2023, 83 (15) : 1425 - 1432
  • [4] Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review
    Delgado, Diego
    Dabbous, Firas
    Shivappa, Nitin
    Mazhar, Faizan
    Wittbrodt, Eric
    Shridharmurthy, Divya
    Jarbrink, Krister
    ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)
  • [5] Alnylam Act®: Heterogenous Disease Manifestations of Hereditary Transthyretin-Mediated Amyloidosis
    Malladi, Ruthvik
    Truty, Rebecca
    Winder, Tom
    Dinh, Quinn
    Melanson, Maria
    Agarwal, Sonalee
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S111 - S112
  • [6] Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
    Tina Nie
    Young-A Heo
    Matt Shirley
    Drugs, 2023, 83 : 1425 - 1432
  • [7] Transthyretin Stabilizers Treatment in Patients With Transthyretin-Mediated Cardiac Amyloidosis: A Systematic Review and Meta-Analysis
    Tanashat, Mohammad
    Bisht, Osama
    Abuelazm, Mohamed
    Altobaishat, Obieda
    Khan, Ubaid
    Abouzid, Mohamed
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (01) : e68 - e78
  • [8] Patisiran in hereditary transthyretin-mediated amyloidosis
    Luigetti, Marco
    Servidei, Serenella
    LANCET NEUROLOGY, 2021, 20 (01): : 21 - 23
  • [9] Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) : 95 - 99
  • [10] Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy
    Ioannou, Adam
    Fontana, Marianna
    Gillmore, Julian D.
    HEART INTERNATIONAL, 2023, 17 (01): : 27 - 35